MoonLake Immunotherapeutics (MLTX) USD0.0001 A
Sell:$38.00Buy:$39.50
$0.03
(0.08%)
- This stock can be held in a
Stocks and Shares ISA$0.03
(0.08%)$0.03
(0.08%)Company Information
About this company
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Key people
Key facts
- EPICMLTX
- LocationSwitzerland
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINKY61559X1045
- Market cap$2.54bn
- Employees100
- Shares in issue63.47m
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.